
Sign up to save your podcasts
Or
Dr. Hilal, of the Mayo Clinic, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss measurable residual disease (MRD) and the debates surrounding its use for response assessment in patients with chronic lymphocytic leukemia (CLL).
4.8
2626 ratings
Dr. Hilal, of the Mayo Clinic, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss measurable residual disease (MRD) and the debates surrounding its use for response assessment in patients with chronic lymphocytic leukemia (CLL).
135 Listeners
111 Listeners
26,356 Listeners
27 Listeners
182 Listeners
2 Listeners
348 Listeners
56 Listeners
366 Listeners
136 Listeners
8 Listeners
29 Listeners
181 Listeners
48 Listeners
40 Listeners